• Users Online: 1088
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most cited articles *

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
REVIEWS
A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase
Peter Y. M. Woo, Yi Li, Anna H. Y. Chan, Stephanie C. P. Ng, Herbert H. F. Loong, Danny T. M. Chan, George K. C. Wong, Wai-Sang Poon
April-June 2019, 2(2):68-82
DOI:10.4103/glioma.glioma_3_19  
  13 8,051 1,000
Molecular mechanisms involved in angiogenesis and potential target of antiangiogenesis in human glioblastomas
Yang Xu, Fan-En Yuan, Qian-Xue Chen, Bao-Hui Liu
March-April 2018, 1(2):35-42
DOI:10.4103/glioma.glioma_10_17  
  9 5,665 669
ORIGINAL ARTICLES
BRAF mutation marks out specific subgroups of glioma
Aden Ka-Yin Chan, Riki Rui-Qi Zhang, Abudumijiti Aibaidula, Zhi Feng Shi, Hong Chen, Ying Mao, Ho Keung Ng
September-October 2018, 1(5):168-174
DOI:10.4103/glioma.glioma_33_18  
  5 5,161 548
REVIEWS
Pediatric high-grade glioma: A heterogeneous group of neoplasms with different molecular drivers
Francesca Gianno, Manila Antonelli, Elisabetta Ferretti, Maura Massimino, Antonietta Arcella, Felice Giangaspero
July-August 2018, 1(4):117-124
DOI:10.4103/glioma.glioma_27_18  
  5 9,781 1,176
Nanoparticles drug-delivery systems and antiangiogenic approaches in the treatment of gliomas
Maria Caffo, Salvatore Massimo Cardali, Elena Fazzari, Valeria Barresi, Gerardo Caruso
November-December 2018, 1(6):183-188
DOI:10.4103/glioma.glioma_43_18  
  5 4,221 453
ORIGINAL ARTICLES
Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma
Steven Lehrer, Peter H Rheinstein, Kenneth E Rosenzweig
July-August 2018, 1(4):132-135
DOI:10.4103/glioma.glioma_17_18  
  4 3,356 385
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
Pingde Zhang, Ning Li, Karrie Mei Yee Kiang, Zhiyuan Zhu, Gloria Wai Man Leung, Stephen Yin Cheng, Gilberto Ka Kit Leung
September-October 2018, 1(5):175-181
DOI:10.4103/glioma.glioma_37_18  
  4 3,760 373
YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression
Yu-Hang Zhao, Zhi-Yong Pan, Ze-Fen Wang, Chao Ma, Hong Weng, Zhi-Qiang Li
May-June 2018, 1(3):104-110
DOI:10.4103/glioma.glioma_16_18  
  4 3,657 355
REVIEWS
Histological approach to neuronal and mixed neuronal-glial tumors of the central nervous system
Char Loo Tan, Roger E McLendon
May-June 2018, 1(3):89-96
DOI:10.4103/glioma.glioma_24_18  
  4 7,493 921
ORIGINAL ARTICLES
Reprogramming glioma cell cultures with retinoic acid: Additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy
Matthieu Dreyfus, Michèle El-Atifi, Magali Court, Marie Bidart, Charles Coutton, Céline Leclech, Bruno Ballester, Emmanuel Garcion, Ali Bouamrani, François Berger, Didier Wion
March-April 2018, 1(2):66-78
DOI:10.4103/glioma.glioma_3_18  
  3 4,491 434
Vasculogenic mimicry persists during glioblastoma xenograft growth
Cong Li, Yin-Sheng Chen, Qing-Ping Zhang, Jian-Liang Chen, Jing Wang, Fu-Rong Chen, Ho-Keung N G, Zhong-Ping Chen
January-February 2018, 1(1):16-21
DOI:10.4103/glioma.glioma_4_17  
  3 4,330 425
REVIEWS
Myeloid-derived suppressor cells and nonresolving inflammatory cells in glioma microenvironment: molecular mechanisms and therapeutic strategies
Xiao-Yan Ji, Jia-Wei Ma, Jun Dong
January-February 2018, 1(1):2-8
DOI:10.4103/glioma.glioma_2_17  
  3 3,924 433
EDITORIAL
The new WHO molecular criteria for adult glioblastoma – Are we a step too far?
Ho-Keung Ng, Queenie Hoi-Wing Wong, Emma Munan Liu, Kay Ka-Wai Li
October-December 2021, 4(4):65-67
DOI:10.4103/glioma.glioma_19_21  
  2 1,741 177
ORIGINAL ARTICLES
Patterns of computed tomographic findings in patients from Maiduguri, Nigeria, diagnosed with a brain tumor
Alhaji Modu Ali, Maryam Abdullahi Buji, Ahmed Abubakar
July-September 2019, 2(3):153-156
DOI:10.4103/glioma.glioma_11_19  
  2 2,787 216
Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report
Chengcheng Guo, Qunying Yang, Jiawei Li, Shaoxiong Wu, Meiling Deng, Xiaojing Du, Ke Sai, Xiaobing Jiang, Zhenghe Chen, Ji Zhang, Fuhua Lin, Jian Wang, Yinsheng Chen, Chao Ke, Xiangheng Zhang, Xue Ju, Yonggao Mou, Jeffrey Bacha, Anne Steino, Sarath Kanekal, Claire Kwan, Gregory Johnson, Richard Schwartz, John Langlands, Dennis Brown, Zhong-ping Chen
October-December 2019, 2(4):167-173
DOI:10.4103/glioma.glioma_25_19  
  2 4,278 298
Evidence of calcium-activated potassium channel subunit alpha-1 as a key promoter of glioma growth and tumorigenicity
Divya Khaitan, Nagendra Ningaraj
January-March 2019, 2(1):46-54
DOI:10.4103/glioma.glioma_44_18  
  2 2,938 224
REVIEWS
Role of natural killer cells in isocitrate dehydrogenase 1/2 mutant glioma pathogenesis and emerging therapies
Xiaoran Zhang, Aleksandra Safonova, Aparna Rao, Nduka Amankulor
July-September 2019, 2(3):133-138
DOI:10.4103/glioma.glioma_10_19  
  2 4,039 378
Current management of glioma in Pakistan
Umm E Hani Abdullah, Altaf Ali Laghari, Muhammad Usman Khalid, Huzaifa Bin Rashid, Adnan Abdul Jabbar, Fatima Mubarak, Asim Hafiz, Shahzad Shamim, Syed Ather Enam
July-September 2019, 2(3):139-144
DOI:10.4103/glioma.glioma_15_19  
  2 4,552 345
Combination of oncolytic viruses and immune checkpoint inhibitors in glioblastoma
Kunal Desai, Anne Hubben, Manmeet Ahluwalia
January-March 2019, 2(1):7-19
DOI:10.4103/glioma.glioma_5_19  
  2 6,143 486
Ongoing evolution of response assessment in glioma: Where do we stand?
Li Yi, Haolang Ming, Shengping Yu, Bingcheng Ren, Xuejun Yang
May-June 2018, 1(3):97-103
DOI:10.4103/glioma.glioma_13_18  
  2 4,698 495
The advances in targeted therapy and immunotherapy for glioblastoma: Basic research and clinical trials
Mei Wang, Xiaochun Jiang, Fubing Wu, Haojun Xu, Zihong Lin, Bin Qi, Hongping Xia
May-June 2018, 1(3):79-88
DOI:10.4103/glioma.glioma_10_18  
  2 6,337 729
Gamma-delta T cells in glioblastoma immunotherapy
Sadhak Sengupta
January-March 2019, 2(1):30-36
DOI:10.4103/glioma.glioma_48_18  
  2 7,178 717
CASE REPORT
Diffuse midline glioma, H3-K27M mutant: Awareness leads to identification
Sadhana Tiwari, Ishita Pant, Sujata Chaturvedi, Gurbachan Singh
January-March 2019, 2(1):55-59
DOI:10.4103/glioma.glioma_1_19  
  1 3,971 283
EDITORIAL
Glioma special issue introduction
Christopher Jackson, Michael Lim
January-March 2019, 2(1):1-2
DOI:10.4103/glioma.glioma_2_19  
  1 3,169 313
ORIGINAL ARTICLES
IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ
Ningning Li, Rui Zhang, Yi Sun, Chenyue Xu, Yin Wang, Ji Xiong, Qi Chen, Ying Liu
January-March 2019, 2(1):37-45
DOI:10.4103/glioma.glioma_46_18  
  1 2,943 242
* Source: CrossRef